Home » Actavis Gets Complete Response Letter for Transdermal Contraceptive Patch
Actavis Gets Complete Response Letter for Transdermal Contraceptive Patch
Actavis’ NDA for a progestin-only transdermal contraceptive patch has been turned down by the FDA, according to the company. The rejection comes about 10 months after the NDA was filed.
Drug Daily Bulletin
Drugs Regulatory Affairs Submissions and ApprovalsDrug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May